Medco, GSK Reach Formulary Agreement For Medicare Part D
This article was originally published in The Pink Sheet Daily
Executive Summary
Medco describes the agreement as an "innovative collaboration" in a press release. Under the deal, Medco and GSK will share responsibility for providing access to and ensuring appropriate use of the products, the PBM said.
You may also be interested in...
Medco Reaches Risk-Sharing Rebate Agreements For 75% Of Part D Spend
The PBM is "very comfortable" that its rebating model is not outside of legal safe harbors, CEO Snow says. Under such formulary agreements, Medco receives incremental rebates when utilization exceeds set levels within a therapeutic category.
Medco Reaches Risk-Sharing Rebate Agreements For 75% Of Part D Spend
The PBM is "very comfortable" that its rebating model is not outside of legal safe harbors, CEO Snow says. Under such formulary agreements, Medco receives incremental rebates when utilization exceeds set levels within a therapeutic category.
GSK Does Not Expect Overly Restrictive Formularies Under Part D
GlaxoSmithKline does not expect formularies under the Medicare Part D drug benefit program to be overly restrictive